动静脉联合治疗中晚期非小细胞肺癌的临床分析  

Efficacy of Bronchial Artery Infusion Combined with Systemic Chemotherapy on Middle and Late Stage Non-Small Cell Lung Cancer

作　　者：韦永明[1] 王银华[1] 周勤[1] 张章[1] 胡俊[1] 章俊[1] 齐志峰[1] 宛新安[1] 

机构地区：[1]安徽省芜湖市第二人民医院肿瘤介入科,241000

出　　处：《中华全科医学》2009年第7期726-728,共3页Chinese Journal of General Practice

摘　　要：目的探讨支气管动脉灌注(BAI)联合全身静脉化疗治疗非小细胞肺癌(NSCLC)的疗效及毒副反应。方法102例均经病理或细胞学证实为NSCLC,行NP方案化疗(盖诺30 mg/m2BAI d1,顺铂80 mg/m2BAI d1,盖诺30 mg/m2iv d8)。结果在可评价的102例病例中,CR 10例,PR 47例,SD 36例,PD 9例。总有效率55.9%;6个月生存率98%,1年生存率71.6%,2年生存率5.9%,3年生存率1.0%,中位生存期14个月。血液毒性反应主要是白细胞减少,其发生率为94.1%,Ⅲ、Ⅳ度白细胞减少占44.1%。多因素分析显示性别、年龄、TNM分期,近期疗效为主要危险因素。结论NP方案动静脉联合治疗中晚期NSCLC具有较好的近期疗效,且毒副反应轻,是治疗中晚期NSCLC的较好方法之一。Objective To investigate the efficacy, side effect and toxicity between bronchial artery infusion （BAI） combining systemic chemotherapy of Navelbine （NVB） plus Cisplatin （DDP） for middle and late stage non-small cell lung cancer（ NSCLC ）. Methods 102 patients with NSCLC in stage Ilia to Ⅳ were administered with BAI plus systemic chemotherapy（ NVB 30 mg/m^2 BAI d1, DDP 80 mg/m^2 BAId1, NVB 30 mg/m^2 iv d8 ）. Results In all 102 eases., 10 achieved CR,47 PR,36 SD and 9 PD,the overall response rate was 55.9%. The 6 month, 1,2 year survival rates were 98.0% ,71.6% and 5.9%. respectively,with a median survival duration of 14 months. In the multivariate analysis, the Sex, age, TNM stage, short term curative effect presented prognostic significance for overall survival （ P 〈 0.05 ）. Conclusion Combining bronchial artery infusion and systemic chemotherapy with NVB plus Cisplatin is an effective, feasible approach in the treatment of advanced non small cell lung cancer （NSCLC）.

关 键 词：非小细胞肺肿瘤 支气管动脉灌注 化疗 盖诺 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]